Floatz logo

OXYMORPHONE CII

Chronic Nociceptive Pain

Icahn School of Medicine at Mount SinaiSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Chronic Nociceptive Pain cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

OXYMORPHONE CII is also rated in:

chronic pain syndromeDormant
B
Indicative ·
62 / 100
View asset →
Lower Back PainDormant
B
Indicative ·
57 / 100
View asset →
opiate dependenceDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →